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As a possible way of making a non-rejectable skin substitute, here, we ask the question of whether the expression
of indoleamine 2,3-dioxygenase (IDO) selectively suppresses immune, but skin, cell proliferation. To address this
question, a series of experiments in which adenovirus (Ad-IDO) infected IDO expressing dermal ﬁbroblasts were
co-cultured with different types of immune cells were carried out. The immune cells were then harvested and
evaluated for propidium iodide (PI) positive cells by FACS analysis. TUNEL assay was also carried out to determine
the apoptotic status of these cells. The results showed that the expression of IDO in dermal ﬁbroblasts signiﬁcantly
induces apoptotic death of PBMC, CD4þ -, CD8þ - and B cell-riched primary lymphocytes, Jurkat cells, and THP-1
cells. IDO-mediated damage of immune cells was restored by an addition of tryptophan and IDO inhibitor. Using the
same approaches, we also demonstrated that skin cells and endothelial cells are remarkably resistant to tryptophan-
deﬁcient environment. Furthermore, no signiﬁcant difference in cell proliferation between Ad-GFP (control)- and
Ad-IDO-GFP-infected either keratinocytes or ﬁbroblasts, was found. The results of this study, therefore, suggest
that the expression of IDO by dermal ﬁbroblasts mediates immune cell damage and this may shed a new light
toward developing a non-rejectable skin substitute in the future.
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Extensive skin loss from a variety of conditions such as
severe thermal injury is associated with significant func-
tional morbidity and mortality (Cairns et al, 1993). In recent
years, however, the overall mortality rate has been improved
for patients suffering from burns due in part to the
significant biotechnological advancements in skin replace-
ment for wound closure (Cairns et al, 1993). In vitro,
cultivation of keratinocytes with the support of a feeder
layer of lethally irradiated 3T3 cells was initially introduced
by Rheinwald and Green (1975). These investigators were
later able to grow keratinocytes to confluency, which was
suitable for grafting (Gallico et al, 1984). Although sheets of
autologous keratinocytes are currently used in some burn
centers to treat patients with large thermal injury (Morhenn
et al, 1982; Thivolet et al, 1986), this has not been a routine
procedure due to: firstly sheets of keratinocytes prepared
from layers of cultured keratinocytes without matrix are very
fragile and difficult to cultivate, secondly the rate of graft-
take is relatively low (50%–60%), thirdly patients with large
injuries do not have enough of uninjured skin to be used for
cell culture, and lastly generating another wound increases
the risk of an infection and development of hypertrophic
scarring. Considering the fact that all of these factors are
pervasive medical problems with far-reaching clinical and
economic implications, utilizing an allogeneic and readily
available skin substitute seems logical to overcome these
problems. Therefore, a series of experiments have been
designed and conducted by our laboratory to examine the
benefit of using allogeneic skin cells expressing indolea-
mine 2,3-dioxygenase (IDO) as a local immunosuppressive
factor.
IDO is a monomeric heme-containing enzyme that
catalyzes the opening of the pyrrole ring of L-tryptophan
to yield N-formylkynurenine, which rapidly degrades to give
kynurenine (Higuchi and Hayaishi, 1967). Interferon (IFN)-g
is a strong inducer of IDO expression in cultured fibroblasts
(Dai and Gupta, 1990a), macrophages (Carlin et al, 1989),
dendritic cells (Hwu et al, 2000), and many cancer cell lines
(Taylor and Feng, 1991). IDO is also induced rather poorly
by LPS (Yoshida and Hayaishi, 1978), IFN-a, and IFN-b
(Bianchi et al, 1988). It is demonstrated that IDO activity
significantly increases in certain pathophysiologic condi-
tions such as transplanted tumor cells (Takikawa et al,
1990), viral transfected lung (Yoshida et al, 1979), and viral
transfected epithelial cells (Jacoby and Choi, 1994). The
role of IDO in the survival of fetal allograft during pregnancy
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has also been explored. Munn et al (1998) reported that the
expression of IDO in the placenta is crucial in the prevention
of immunological rejection of the fetal allograft. These
investigators suggested that proliferation of infiltrated Tcells
was inhibited by IDO, as it generates a tryptophan-deficient
environment in the placenta. In vitro studies have also
demonstrated that IDO expression by macrophages (Munn
et al, 1999) and dendritic cells (Hwu et al, 2000) inhibits
bystander lymphocyte proliferation.
Considering the protective role of IDO in maternal T cell-
mediated rejection of allogenic fetuses (Munn et al, 1998;
Mellor et al, 2001) and the success of IDO in prolonging the
survival of pancreatic islet cells (Alexander et al, 2002), we
hypothesize that IDO expression may function as a local
immune suppressive factor to protect allogenic skin sub-
stitutes. In this study, we, therefore, constructed and used
recombinant adenoviral vectors bearing either green fluor-
escent protein (GFP) as a marker or GFP-IDO genes to
infect dermal fibroblasts. Co-culturing IDO genetically
modified fibroblasts with different types of immune cells,
we demonstrated a significant increase in damage of
bystander human peripheral blood mononuclear cells
(PBMC), CD4þ -, CD8þ -, and B cell-enriched lymphocytes,
CD4-positive Jurkat cells, and THP-1 cells relative to those
of controls. This bystander effect proved to be due to IDO
inducing a tryptophan-deficient cell culture environment. In
addition, considering the fact that IDO expression seems to
affect only the infiltrated immune, but not the non-immune
cells in these tissue environments, here, we also hypothe-
size that skin cells such as keratinocytes and fibroblasts
would survive and proliferate in IDO generating tryptophan-
deficient environment. Using the same approaches, in this
study, we demonstrated that fibroblasts would survive even
after 15 d of being cultured in a low tryptophan environ-
ment. Both keratinocytes and endothelial cells co-cultured
with IDO-expressing cells were also viable up to 5 d
examined. These results suggest that the expression of IDO
by dermal fibroblasts could function as a local immuno-
suppressive factor for prevention of rejection of grafted skin
substitutes.
Results
Adenoviral vector-infected cells expressed IDO and GFP
proteins To distinguish the IDO-infected cells from unin-
fected cells and to evaluate the level of IDO expression in
these cells, we employed an adenoviral vector bearing the
GFP gene, as a reporter gene, to construct a human IDO
plus GFP recombinant adenoviral vector. As shown in the
schematic diagram Fig 1A, the CMV5 promoter drives the
expression of either GFP in control or IDO plus the GFP in
the recombinant IDO vector. Recombinant human IDO gene
and its correct orientation has been confirmed by serial
restriction enzyme digestions and mapping (data not
shown). A PCR analysis of the viral DNA product confirmed
the successful transfection of IDO recombinant gene in
packaging 293 cells (Fig 1B). Microscopic evaluation of Ad-
GFP- (Fig 1Ca) and Ad-IDO-GFP- (Fig 1Cb) infected 293
cells showed a bright green fluorescent stained, indicating
GFP expression in these cells. To further validate the
biological activity of IDO protein, the levels of tryptophan
and its IDO-generated degraded product, kynurenine, in
conditioned medium derived from Ad-IDO-infected and
non-infected 293 cells, were evaluated by LC–MS. As
shown in Fig 2, the level of tryptophan (panel A) was almost
undetectable in conditioned medium obtained from Ad-
IDO-infected cells relative to that of either non-infected or
Ad-GFP-infected controls, whereas the level of kynurenine
(panel B) was more than 20-fold higher in the same
conditioned medium.
In a similar experimental setting, fibroblasts, keratino-
cytes, and endothelial cells were separately infected with
mock or IDO recombinant adenovirus and evaluated for
efficacy of transfection. As shown in Fig 3A, after 72 h post-
infection, more than 90% keratinocytes and endothelial
cells were successfully transfected and were positive for
GFP protein. Fibroblasts, however, had lower efficacy of
Ad-GFP-IDO transfection compared with the other two cell
types used. The number of GFP-positive fibroblasts was
about 30%–50% as evaluated by FACS analysis (data not
shown). To confirm these findings, the expression of IDO
protein in Ad-GFP-IDO-infected fibroblasts, keratinocytes,
and endothelial cells harvested at 72 h post-infection was
analyzed by western blot using rabbit polyclonal anti-human
IDO. As shown in Fig 3B, an anti-IDO antibody immunor-
ecognized a 42 kDa band in IDO recombinant adenovirus-
infected cells. The size of protein was consistent with the
expected molecular weight of human IDO (Dai and Gupta,
1990b). Consistent with IDO protein expression, a signifi-
cant increase in the levels of kynurenine, used as an index
for IDO activity, was found in only Ad-GFP-IDO-infected
fibroblasts and keratinocytes (data not shown).
IDO expression mediates bystander immune cell apop-
tosis To examine the mediating role of IDO expression in
bystander immune cell damage, total human PBMC, CD4þ -,
CD8þ -, and B cell-enriched cells as well as CD4þ Jurkat
cells, THP-1 monocytes as non-IDO-expressing bystander
cells, were employed. In these experiments, IDO-infected
human dermal fibroblasts were used as IDO-expressing
cells, and non-adenoviral-infected and Ad-GFP-infected
fibroblasts were used as controls. After 30 h of fibroblast
infection and following confirmation of IDO and GFP
expression on day 4 post-infection, cells were co-cultured
with immune cells. After 3–5 d, bystander co-cultured
immune cells were then harvested and evaluated for PI
staining by FACS analysis. As shown in Fig 4A, almost all
immune cells used are sensitive to IDO-induced low
tryptophan environment. The highest number of PI-positive
cells was found in the CD4þ lymphocyte population (30%)
relative to either PBMC (18%), CD4þ - (16%), and B cell-
enriched (16.4%) population. The number of PI-positive
immune cells was the same when they were co-cultured
with either non- or AD-GFP-infected cells. Similarly, the
number of PI-positive Jurkat and THP-1 cells was more
than 16-fold (82.7% vs 5.2%) and 8-fold (35.8% vs 3.9%),
respectively, higher when cells co-cultured with Ad-IDO-
infected fibroblasts compared with those co-cultured with
mock-infected fibroblasts (Fig 4B).
To further demonstrate that IDO induction is the main
cause of bystander immune cell damage, IFN-g as a strong
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IDO inducer (Dai and Gupta, 1990a) was used to treat
dermal fibroblasts as a source of IDO induction. The
induction of IDO mRNA expression was confirmed by
northern analysis; whereas the activity of IDO was mon-
itored by measuring the level of kynurenine in condition
medium by LC–MS (data not shown). After confirmation of
IDO induction and activity, fibroblasts were co-cultured with
CD4þ Jurkat cells for another 4 d. Unattached Jurkat cells
were then harvested and stained with PI. The number of PI-
positive cells were evaluated by FACS analysis. As shown in
Fig 4C, the number of PI-positive Jurkat cells co-cultured
with IFN-g pre-treated fibroblasts increased more than
25-fold (77% vs 3%) relative to those co-cultured with IFN-g
untreated fibroblasts. This result thus provides further
evidence that IDO expression causes bystander immune
cell damage.
To investigate whether the mediating role of IDO in
bystander immune cell damage is due to apoptosis, PI
staining, TUNEL assay and nuclear fragmentation were
used. The results of the microscopic PI-stained cells
revealed a typical nuclear fragmentation, a hallmark of
apoptosis, in Jurkat cells co-cultured with IDO-expressing
fibroblasts for 3 d (Fig 5A). Consistent with PI staining
results, the finding of TUNEL assay demonstrated a large
number of apoptotic Jurkat cells co-cultured with either
IFN-g pre-treated fibroblasts (Fig 5Bb) or Ad-IDO-infected
fibroblasts (Fig 5Cc). In contrast, no sign of apoptotic cells
was found in Jurkat cells co-cultured with either non-
infected (Fig 5Ba and Ca) or Ad-GFP-infected (Fig 5Cb)
cells. Furthermore, a typical DNA ladder, as another index
for apoptosis, was also seen in Jurkat cells co-cultured with
IDO-expressing fibroblast (data not shown). These results
collectively suggest that IDO expression is responsible for
the apoptosis of bystander immune cells in our co-cultured
system.
Addition of tryptophan and IDO inhibitor restored
immune cell damage induced by IDO To test the possible
mechanism through which IDO mediates bystander cell
damage, we examined the effect of tryptophan and its
degraded product, kynurenine to see whether the expres-
sion of IDO-induced immune cell damage is due to
kynurenine toxicity or tryptophan depletion. The results
showed that an addition of kynurenine at various concen-
trations ranging from 40 to 400 mM to the conditioned
medium of cultured THP-1 cells and Jurkat cells has no
cytotoxic effect on these cells (data not shown). But an
addition of L-tryptophan to conditioned medium of either of
these cell types markedly decreased bystander cell
damage. As shown in Fig 6, the number of PI-positive
Jurkat cells and THP-1 co-cultured with IDO-expressing
fibroblasts markedly reduced, from 83% to 13% and 33%
to 3%, respectively. To confirm these results, a specific IDO
inhibitor, L-methyl D-tryptophan, was added to conditioned
medium at a concentration of 800 mM. As expected, the
number of PI-positive Jurkat and THP-1 cells co-cultured
with IDO-expressing fibroblasts markedly reduced from
82% to 25% and from 33% to 5.4%, respectively.
Skin cells and endothelial cells are resistant to IDO-
induced low tryptophan culture environment To assess
the mediating role of IDO expression in bystander primary
Figure 1
Schematic diagram of constructed human IDO, its PCR gene product and microscopic appearance of GFP expression. IDO was initially
cloned into a shuttle vector, pAdenoVator-CMV5-IRES-GFP. Constructed plasmid was then linearized by PmeI restriction endonuclease and inserted
into an adenoviral backbone plasmid, pAdenoVator DE1/DE3, and used to transform Escherichia coli BJ5183 cells (panel A). Finally, the linearized
recombinant IDO plasmid was used to transfect adenoviral packaging 293 cells using Fugene-6 transfection kit. After 10 d, a high titer of IDO
adenoviral particles was confirmed in 293 cells and the conditioned medium of transfected cells was used to infect the other cell strains. Panel B
shows the PCR product detected in IDO-infected 293 cells using PCR procedure and specific IDO primers described in the Materials and Methods.
Panel C shows microscopic appearance of GFP expression in 293 cells infected at a multiplicity of infection of 5 with either Ad-GFP (panel Ca) or Ad-
GFP-IDO (panel Cb) for 3 d. IDO, indoleamine 2,3-dioxygenase; GFP, green fluorescent protein.
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skin cells and endothelial cells, either Ad-GFP- or Ad-GFP-
IDO-infected keratinocytes, endothelial cells (Fig 7A), and
fibroblasts (Fig 7B) were co-cultured with its corresponding
non-infected cells, respectively. Cells from the bottom
chambers (non-infected cells) were harvested and stained
with PI. Positive cells were determined by FACS analysis. As
shown in Fig 7A, only 2.6% of keratinocytes grown in IDO-
induced tryptophan depleted medium were PI positive after
5 d of culture. Similarly the number of PI-positive endothelial
cells (Fig 7A) and fibroblasts (Fig 7B) grown in the same
environment for 5 d was less than 3.5%. When this duration
was extended to 15 d for dermal fibroblasts, no significant
difference in numbers of PI-positive fibroblasts between Ad-
GFP- and Ad-GFP-IDO-infected cells was found (Fig 7B).
These results reveal that primary skin cells such as
keratinocytes and fibroblasts as well as endothelial cells
are resistant to IDO-generated low tryptophan environment,
at least, for the indicated durations examined.
IDO does not alter proliferative capacity of infected
ﬁbroblasts and keratinocytes To examine whether IDO
expression influences the proliferative capacity of IDO-
expressing cells, either fibroblasts (Fig 8A) or keratinocytes
(Fig 8B) were infected with either nothing (column C),
Ad-GFP (column V), or Ad-GFP-IDO (column IDO). Cell
proliferation was then evaluated by [3H]thymidine incorpora-
tion after 3 and 6 d post-infection. As shown in Fig 8A,
infected fibroblasts showed less [3H]thymidine incorpora-
tion at both time points examined relative to those of non-
infected cells (column C, po0.05). Similarly, infected
keratinocytes (Fig 8B) also showed less [3H]thymidine
incorporation at day 3 (po0.05). The rate of cell proliferation
between infected and non-infected keratinocytes, however,
did not show a significant change at day 6 (p40.05).
Compared with Ad-GFP-infected fibroblasts or keratino-
cytes, proliferation of Ad-GFP-IDO-infected fibroblasts was
higher at both time points (po0.05) and higher for IDO-
expressing keratinocytes at day 3 (po0.05). These results
may imply that adenovirus, but not IDO expression, is
responsible for the suppression of IDO-expressing fibro-
blast and keratinocyte proliferation.
Discussion
Considering the fact that an ultimate goal of any tissue
engineering related study is to explore the possible
approaches through which the clinical complications of
both non-healing and over-healing wounds are improved,
there is a need to develop a non-rejectable and readily
available skin substitute. This skin substitute would function
as a wound coverage to prevent or reduce heat and fluid
loss, and to prevent wound infection. The skin substitute
should also function as a wound coverage through which
dermal–epidermal wound-healing modulating factors are
released locally to facilitate granulation tissue formation,
re-epithelialization, and improve closure of non-healing
wounds, such as those seen in the diabetic patients.
Different approaches have been attempted for temporary or
permanent coverage of wounds. Synthetic dressings (e.g.
Integra and Dermagraft artificial skin) and biological dres-
sings (e.g. Alloderm and Apligraf artificial skin) have been
developed for the last 30 y (Philips 1998). Two products with
allogeneic components are commercially available. Derma-
graft consists of living allogeneic dermal fibroblasts grown
on degradable scaffold. Apligraf is a living allogeneic
bilayered construct containing keratinocytes, fibroblasts,
and bovine collagen. Although, these skin substitutes have
not been shown to be immunogeneic by limited clinical
data, the potential risks of acute and chronic rejection of
allograft need to be further evaluated (Briscoe et al, 1999;
Badiavas et al, 2002). Previous studies have shown that
even in the absence of passenger leukocytes and langer-
hans cells, cultured allogeneic skin cells used as a wound
coverage were rejected (Aubock et al, 1988; Phillips, 1991;
Rouabhia et al, 1993). Furthermore, a recent study by
Lamme et al (2002) demonstrated that allogeneic fibroblasts
in a dermal skin substitute induce inflammation and scar
formation. Engineered skin substitutes using the patient’s
skin cells are far more desirable. But it is difficult to perform
an autologous engraftment for patients who suffer from
extensive skin loss from a variety of conditions such as
Figure 2
Tryptophan and kynurenine levels in conditioned medium of
cultured 293 Cells with or without recombinant adenoviral infec-
tion. To examine the IDO enzyme activity, the conditioned medium
derived from either non-infected, Ad-GFP-, or Ad-IDO-GFP-infected
cells was collected and evaluated for the levels of either tryptophan
(panel A) or kynurenine (panel B) using the liquid chromatography with
electrospray mass spectrometry procedure described in the Materials
and Methods. IDO, indoleamine 2,3-dioxygenase; GFP, green fluor-
escent protein.
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large and severe thermal injury due to limited amount of
uninjured tissue. This is also true for diabetic, elderly, and
immune-compromised patients who suffer from non-heal-
ing complications. Therefore, exploring an allogeneic, non-
rejectable, and readily available skin substitute may provide
a better means of improving wound healing. As rejection is a
major obstacle in any type of grafting, this study
seeks a novel approach through which local induction of
immunosuppressive factors, such as IDO, a tryptophan
catabolizing enzyme, generates a tryptophan-deficient
microenvironment in which immune cells are unable to
survive.
Figure 3
Efficiency of IDO transfection in fibro-
blasts, keratinocytes and endothelial
cells using an adenovirus recombi-
nant system (A) GFP expression in
fibroblasts (upper panel), keratinocytes
(medium panel), and endothelial cells
(lower panel) after 72 h infection with
either Ad-GFP (left panel) or Ad-IDO-
GFP (right panel) . Fibroblasts, keratino-
cytes, or endothelial cells were infected
with either Ad-GFP or Ad-IDO-GFP at indi-
cated multiplicity of infection of 2000,
100, 100, respectively. The extent of
infection was monitored by GFP expres-
sion under fluorescence microscopy.
Magnification  100. (B) Western blot
analysis of IDO expression. Fibroblasts,
keratinocytes, or endothelial cells were
infected with either Ad-GFP or Ad-IDO-
GFP for 72 h. Non-infected and infected
cells were harvested, and cell lysates
were fractionated by SDS-PAGE. IDO
protein was detected using a polyclonal
antibody from rabbit immunized with a
purified recombinant IDO protein. Arrow
shows a 42 kDa band corresponding to
the IDO protein. GFP, green fluorescent pro-
tein; IDO, indoleamine 2,3-dioxygenase.
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As a part of a series of experiments, here, we
constructed two human adenoviral vectors bearing either
GFP as a reporter gene or IDO plus GFP genes and
demonstrated that dermal fibroblasts can successfully be
infected and the resultant IDO is catalytically active in
degradation of tryptophan, an essential amino acid required
for protein synthesis. In a co-culture system, the IDO
expression in dermal fibroblasts generated a tryptophan-
deficient environment in which the majority of immune cells
such as PBMC, CD4þ , CD8þ , B cells, Jurkat cells, and
THP-1 monocytes were unable to survive. As the same
adenoviral vector (Ad-GFP vector) was used as a negative
control, any alteration in immune cell damage should
be due to the expression of IDO itself. The number of PI-
positive Jurkat cells co-cultured with IFN-g pre-treated
fibroblasts increased more than 25-fold relative to those co-
cultured with IFN-g non-treated fibroblasts. This result
provides further evidence that it is IDO expression and not
adenoviral components that causes bystander immune cell
damage.
A role for cell expressing IDO in inhibiting immune
responses in vivo is consistent with that previously reported
in murine pregnancy, grafted IDO-expressing islets, and
IDO-expressing tumor cells injected into mice (Munn et al,
1998; Alexander et al, 2002; Mellor et al, 2002). In this
regard, it has been hypothesized that IDO expression by
either trophoblasts and macrophages in placenta, or IDO-
infected islets and tumor cells, helps to maintain peripheral
tolerance through regulating allogeneic T cell response.
Indeed, in vitro studies showed that monocyte-derived
macrophages exposed to macrophage colony-stimulating
factor (MCSF) acquire the capacity to suppress T cell
proliferation by inducing IDO expression (Munn et al, 1999).
Similarly, Hwu et al (2000) reported that the proliferation of
OKT3-stimulated autologous T cells is also inhibited by IDO
producing dendritic cells. These, as well as similar findings
obtained with IDO recombinant adenovirus transduced
dendritic cells (Terness et al, 2002) support the hypothesis
that IDO expression by antigen-presenting cells is respon-
sible for suppression of ‘‘unwanted’’ T cells. During
pregnancy, however, IDO expression is restricted to the
maternal–fetal interface (Sedlmayr et al, 2002). Similarly, the
expression of IDO in genetically modified islets and tumor
cells is also found locally. These findings suggest that local
expression of IDO by skin cells is likely to function as a local
immunosuppressive factor for infiltrated immune cells at the
wound site. Others have suggested that tryptophan
deprivation causes activated T cell apoptosis induced by
expression of FasL (Lee et al, 2002). It is also reported that a
tryptophan metabolite, 3-hydroxyanthranilic acid induces
THP-1 and U937 cell apoptosis (Morita et al, 2001).
Collectively, these results indicated that bystander immune
Figure 4
FACS analysis of PI positive bystander immune cells. (A) Non-viral-infected (control) and pre-infected fibroblasts with either an empty vector (Ad-
GFP) or IDO adenoviral vector (Ad-GFP-IDO) were co-cultured with either human PBMC, CD4þ -, CD8þ -, or B cell-enriched immune cells for 5 d,
respectively. The immune cells were then harvested and stained with 10 mg per mL of PI for 10 min and analyzed by FACS. (B) Non-viral-infected
(control) and pre-infected fibroblasts with either an empty vector (Ad-GFP) or IDO adenoviral vector (Ad-GFP-IDO) were co-cultured with either
CD4þ Jurkat cells or THP-1 monocytes for 3 d, respectively. The bystander immune cells were then harvested and stained with 10 mg per mL of PI
for 10 min and analyzed by FACS. (C) CD4þ Jurkat cells were co-cultured with either non-treated fibroblasts or IFN-g pre-treated fibroblasts for 4 d.
Jurkat cells were then harvested and stained with 10 mg per mL of PI for 10 min and analyzed by FACS. FACS, fluorescence-activated cell sorting; PI,
propidium iodide; GFP, green fluorescent protein; IDO, indoleamine 2,3-dioxygenase; PBMC, peripheral blood mononuclear cells; IFN, interferon.
Figure 5
PI-positive cell microscopic appear-
ance and apoptosis of bystander
immune cells. To evaluate nuclear frag-
mentation of apoptotic bystander im-
mune cells (panel A), IDO-expressing
cells were co-cultured with Jurkat cells
for 3–4 d. Jurkat cells were then
harvested and stained with 10 mg per
mL of PI. The PI-positive cells were
visualized under fluorescent microscope
(original magnification  400). Panels
Aa and Ab are Jurkat cells co-cultured
with either IFN-g-treated fibroblasts or
Ad-GFP-IDO transfected fibroblasts, re-
spectively. For TUNEL assay, Jurkat cells
were co-cultured with either non-treated
fibroblasts (panel Ba) or IFN-g pre-
treated fibroblasts (panel Bb) for 4 d.
Junkat cells were harvested and then
subjected to TUNEL assay to determine
the apoptotic cells. In a similar experi-
ment (panel C), Jurkat cells were co-
cultured with either non-infected (a), Ad-
GFP-infected (b), or Ad-GFP-IDO-infected
(c) fibroblasts for 3 d and then subjected
to TUNEL assay. PI, propidium iodide;
IDO, indoleamine 2,3-dioxygenase; IFN,
interferon; GFP, green fluorescent protein;
TUNEL, terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP-biotin Nick
end labelling.
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cell damage induced by IDO maybe a key contributor for
IDO mediating immune tolerance.
To gain insights into the mechanisms of IDO-induced
apoptosis of immune cells, we evaluated the effects of an
addition of tryptophan and its catabolite, kynurenine, in
conditioned medium and demonstrated that an addition of
tryptophan restored the bystander effects of IDO expres-
sion for co-cultured immune cells. In contrast, an addition of
kynurenine to conditioned medium failed to induce immune
cell damage. This is consistent with previous studies
indicating that depletion of tryptophan is involved in human
IFN-g-mediated apoptosis (Konan and Taylor, 1996).
Furthermore, we have demonstrated that IDO inhibitor at
a concentration previously reported (Sarkhosh et al, 2003)
also prevents the mediating effect of IDO in bystander cell
damage. Collectively, these results suggest that depletion
of tryptophan, but not kynurenine toxicity, is the main
mechanism by which IDO expression induces bystander
immune cell damage.
Although, we have demonstrated that IDO-mediated
activated immune cell damage via tryptophan depletion of
culture environment, the degree of cell sensitivity to low
tryptophan environment seems to vary from one cell strain
to another. As shown in Fig 4, the number of PI-stained
CD4þ Jurkat cells co-cultured with IDO-expressing fibro-
blasts was markedly higher than those of THP-1 monocyte
cells. Similarly, CD4þ -enriched lymphocytes were more
sensitive to a tryptophan-deficient environment compared
with CD8þ - and B cell-enriched lymphocyte population. It
is not clear why there is a great variation in sensitivity of
these immune cells to low tryptophan environment. It seems
that high proliferating immune cells such as Jurkat cells are
more sensitive to tryptophan-deficient environment than
other cells. It should be emphasized that primary skin cells
such as dermal fibroblasts, keratinocytes, and endothelial
cells seem to be more resistant to low tryptophan than
immune cells (Fig 7). As the success of making a non-
rejectable skin substitute depends on skin cell survival in
IDO-generated low tryptophan environment, it would be
encouraging to see that primary skin cells, but not immune
cells, are resistant to an IDO-induced tryptophan-deficient
environment. Consistent with this data, our preliminary
in vivo experimental data using a fibroblast embedded
collagen as wound coverage clearly showed that the
tryptophan-deficient environment generated by IDO is not
toxic to the normal wound-healing processes. Surprisingly,
grafting IDO-expressing fibroblasts embedded collagen gel
would accelerate wound healing and closure compared
with untreated wounds, untreated fibroblasts and adenovir-
al vector-infected fibroblasts embedded collagen gel (data
not shown). The feasibility of usage of IDO-infected skin
cells embedded collagen gel as wound coverage is under
our current investigation.
In conclusion, we constructed an adenoviral vector
bearing IDO gene and for the first time demonstrated that
dermal fibroblasts expressing IDO generated a tryptophan-
deficient microenvironment in which majority of immune
cells were unable to survive. Further we also showed that
primary skin cells are less sensitive to IDO-generated
tryptophan-deficient environment. This differential sensitiv-
ity seen between immune and primary cells would make our
attempt easier in preparing a non-rejectable allogeneic skin
substitute to be used not only as wound coverage but also
as a rich source of wound-healing promoting factors. Thus,
the finding of this study just initiates a new approach
through which the feasibility and benefit of a local
immunosuppressive factor such as IDO in development of
a non-rejectable skin substitutes is evaluated.
Figure 6
Addition of tryptophan prevents the IDO-induced apoptosis of bystander cells. Jurkat cells (panel A) or THP-1 monocytes (panel B) were co-
cultured with Ad-IDO-infected fibroblasts in the presence (right panel) and absence (left panel) of 250 mM of L-tryptophan for 3 d. The immune cells
were then harvested, stained with 10 mg per mL of PI, and the number of PI-positive cells was determined by fluorescence-activated cell sorting
analysis. IDO, indoleamine 2,3-dioxygenase; PI, propidium iodide.
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Figure 7
FACS analyses of PI-positive bystander skin cells and endothelial cells. Either keratinocytes (panel A, upper panel) or endothelial cells (panel A,
lower panel) were co-cultured with either Ad-GFP- (left) or Ad-IDO-GFP- (right) infected cells for 5 d in a two-chamber co-culture system. The non-
infected cells from bottom chambers were harvested and stained with PI. FACS analysis was used to determine the number of PI-positive cells. In
the similar experimental conditions, Foreskin human fibroblasts (panel B) were co-cultured with pre-infected fibroblasts by either Ad-GFP control
(left) or Ad-IDO-GFP (right) for 5, 10, and15 d. The non-infected fibroblasts were harvested and stained with PI for FACS analysis. FACS,
fluorescence-activated cell sorting; PI, propidium iodide; GFP, green fluorescent protein; IDO, indoleamine 2,3-dioxygenase.
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Materials and Methods
Immune and non-immune cell cultures Following informed
consent, skin punch biopsies were obtained from patients under-
going elective reconstructive surgery, under local anesthesia,
according to a protocol approved by the University of Alberta
Hospitals Human Ethics Committee. Biopsies were collected
individually and washed three times in sterile Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen Life Technologies, Carlsbad,
CA) supplemented with antibiotic–antimycotic preparation (100 U
per mL penicillin, 100 mg per mL streptomycin, 0.25 mg per mL
amphotericin B) (Invitrogen). Cultures of fibroblasts were estab-
lished as previously described (Karimi-Busheri et al, 2002). Upon
reaching confluence, the cells were released by trypsinization, split
for subculture at a ratio of 1:6, and reseeded onto 75 cm2 flasks.
Fibroblasts at passages three to seven were used in all experi-
ments conduced in this study.
To establish cultured keratinocytes, the procedure of Rheinwald
and Green (1975) was used. Human foreskin keratinocytes were
grown using serum-free keratinocyte medium (KSFM, Invitrogen)
supplemented with bovine pituitary extract (50 mg per mL) and EGF
(5 mg per mL).
Human umbilical vein endothelial cells (HUVEC) were isolated
by collagenase digestion (Narumiya et al, 2001) and grown on
gelatin-coated flask in M199 medium (Invitrogen) supplemented
with 20% fetal bovine serum (FBS) and endothelial cell growth
supplement (ECGS) (VWRCanlab, Mississauga, ON, Canada) at a
final concentration of 10 mg per mL.
The Jurkat cells (ATCC) and THP-1 (ATCC) were maintained in
RPMI 1640 containing 10% FBS and 2 mM glutamine. Human
PBMC were isolated from donor blood by Ficoll-paque Plus
(Amersham/Pharmacia Biotech, QC, Canada) and cultured in RPMI
1640 containing 10% FBS and 2 mM glutamine. Either CD4þ -,
CD8þ -, or B cell-enriched lymphocyte population was purified by
RosetteSep Cell Enrichment Kit (Stem Cell Technologies, Vancou-
ver, BC, Canada). In brief, 4 mL of whole blood was incubated with
the antibody-based enrichment cocktail at room temperature for
20 min. The RosetteSep antibody cocktail cross-linked unwanted
cells in human whole blood to multiple red blood cells, forming
immunorosettes. Following a standard buoyand density separa-
tion, either CD4þ -, CD8þ -, or B cell-enriched lymphocytes were
harvested, washed by phosphate-buffered saline (PBS), and
cultured in RPMI 1640 containing 10% FBS and 2 mM glutamine.
All these cells were cultured at 371C in an atmosphere of 5% CO2
and 95% air. All media contained 100 U per mL penicillin and 100 U
per mL streptomycin.
Construction of IDO adenoviral vectors and measurement of
IDO enzyme activity Full-length human IDO gene was kindly
provided by Dr J. M. Carlin (Department of Microbiology, Miami
University, Oxford, Ohio). Following amplification by PCR, the IDO
gene was subcloned into a shuttle vector containing a GFP gene
according to manufacturer’s instructions (Q-Biogene, Carlsbad,
CA). The cloned plasmid was then homologously recombined with
adenoviral plasmid in Escherichia coli, BJ5183, by electroporation.
The success of IDO insertion into adenoviral plasmid was
confirmed by restriction endonuclease mapping. Plasmid DNA
was amplified in competent DH5a bacteria and purified by CsCl
gradient in an ultracentrifuge. Adenoviral vectors carrying either
GFP alone or GFP plus IDO gene were linearized by PacI digestion
and used to transfect 293A package cells using Fugene-6
transfection reagent (Roche, Laval, OC, Canada). Infected cells
were monitored for GFP expression and after three cycles of
freezing in an ethanol/dry ice bath and rapid thawing at 371C, the
cell lysates were used to amplify viral particles in large scale. The
viral titre and multiplicity of infection (MOI) was determined
in a 96-well plate according to the manufacturer’s instructions. To
further confirm the success of IDO gene transfection, the 293
transfected and untransfected cell lysates were prepared, DNA
was extracted and the presence of IDO gene was confirmed by
PCR analysis using sense (50-GACTACAAGAAAGAGTACCA-30)
and antisense (50-TTGGGTTA CATTAACCTTCC-30) IDO gene
primers.
The expression and biological activity of the IDO was evaluated
by microscopic evaluation of GFP-positive cells and measuring the
level of tryptophan and its degraded product, kynurenine, present
in conditioned medium derived from IDO and control vector-
infected cells. The conditioned medium related to the same
number of cells was deproteinized by adding 100 mL of acetone
to 50 mL of cell culture medium. It was vortexed for 30 s, cooled on
ice for 5 min, and centrifuged at 16,000 g at 41C for 15 min. The
supernatant of each sample received 10 mL of 0.25 M HClO4 and IS
(4-amino-hippuric acid) solution and then the mixture was
incubated at 251C for 20 min and then dried under a vacuum.
One hundred microliters of 14% BF3-propanol was then added and
the mixture was heated at 901C for 2 h. The vacuum dried material
was dissolved in 40 mL of 20% methanol in water and analyzed by
liquid chromatography with electrospray mass spectrometry (LC/
MS Agilent Technologies Canada, Inc., Mississauga, ON Canada)
using a Hewlett Packard series 1100 mass selective detector
controlled by 1100-MSD Chem. Station. The mass spectrometer
was operated in positive ion mode. Tryptophan and kynurenine
quantitative analyses were performed in the selected ion-monitor-
ing mode.
Figure 8
Effect of IDO on proliferative capacity of fibroblasts and keratino-
cytes. Fibroblasts (panel A) were infected with either Ad-GFP (V) or Ad-
IDO-GFP (IDO) at multiplicity of infection (MOI) of 2000. After 30 h, free
viral particles were removed by washing with phosphate-buffered
saline and incubated up to day 3 or 6 post-infection. After addition of
1 mCi per mL of [3H]thymidine, cell proliferation was determined and
compared with the proliferation of non-infected control cells (C).
Similarly, keratinocytes (panel B) were infected with either Ad-GFP or
Ad-IDO-GFP at MOI of 100 for 30 h. Cell proliferation was determined
at days 3 and 6. Each graph is a representative experiment of four
repeats. Values presented are means  SD for four samples. po0.05,
control (C) versus either vector alone (V) or Ad-GFP-IDO (IDO). IDO,
indoleamine 2,3-dioxygenase; GFP, green fluorescent protein.
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Detection of IDO protein by western blotting For detection of
IDO expression, non- (C), Ad-GFP- (V), or Ad-GFP-IDO- (IDO)
infected cells were harvested after 72 h post-infection and washed
twice with PBS. Cells were then lyzed in lysis buffer (50 mM Tris-
HCl, pH 7.4, 10 mM EDTA, 5 mM EGTA, 0.5% NP40, 1% Triton
X-100, and protease inhibitor cocktail (Sigma, Sigma Chemicals,
Oakville, ON, Canada)). Cell lysate was centrifuged at 16,000 g
for 15 min. The protein concentration of supernatant was
measured by BCA protein assay kit (Pierce, Rockfield, IL). Equal
amounts of total protein were separated by 12% SDS-PAGE and
immunoblotted with our recently raised rabbit polyclonal IDO
antibody at final concentration of 1:5000. Horseradish peroxidase-
conjugated goat anti-rabbit IgG served as a secondary antibody
for the enhanced chemiluminescence detection system (ECL;
Amersham).
Viral infection and cell co-culture system Human fibroblasts,
keratinocytes, and endothelial cells were separately infected with
either Ad-IDO or control viral vectors for 30 h at an MOI of 2000,
100, and 100, respectively. The expression of IDO was confirmed
by: (1) monitoring GFP expression under fluorescence microscopy
(Nikon, Melville, NY HB-1010 AF); (2) measuring the level of
kynurenine in conditioned medium; and (3) the detection of IDO
protein expression using western blot. Infected cells were then
washed twice with PBS to remove the viral particles and then sub-
cultured in six-well plates for co-culture assays. Fibroblasts and
immune cells were co-cultured into a two-chamber culture plate in
which 0.4 mm insert (Millipore, Bedford, MA) separates the upper
(fibroblasts) chamber from the bottom (immune cells). An RPMI
1640 culture medium containing 10% FBS and 2 mM glutamine, a
suitable culture medium for both immune cells and fibroblasts, was
used in this co-cultured assay. Immune cells were harvested at the
different time points. Similarly, using a two-chamber co-culture
system, either Ad-GFP- or Ad-IDO-GFP-infected cells were co-
cultured with non-infected either keratinocytes or fibroblasts or
endothelial cells for different durations. Cells (non-infected
cells) from bottom chambers were harvested, stained and sub-
sequently evaluated by fluorescence-activated cell sorting (FACS)
analysis.
IFN treatment In another approach to induce IDO expression in
dermal fibroblasts (Sarkhosh et al, 2003), cells were treated with
1000 U per mL of IFN-g (GIBCO) or vehicle alone for 40 h to
stimulate the expression of IDO to its maximal level. The cells were
then washed twice with PBS to remove the IFN-g and co-cultured
with Jurkat cells for another 4 d. The IDO activity in fibroblasts
induced by IFN was monitored by measuring the level of kyrurenine
in conditioned medium as previously described.
Propidium iodide (PI) staining and ﬂow-cytometric
analysis Harvested cells were stained with 10 mg per mL of PI
(Sigma) for 10 min. Stained cells were centrifuged and washed
twice with fresh medium. Fluorescence microscopy (Nikon,
HB-10101AF) was used to monitor the pattern of PI-stained
cells and flow cytometry (FACScan, Becton-Dickinson, CO,
Mountain View, CA) was used to quantify the number of PI-positive
cells.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-
biotin Nick end labelling (TUNEL) Cyto-spinned cells were fixed
with acetone:methanol (1:1) for 10 min at room temperature,
washed three times with PBS, then subjected to TUNEL assay. The
fixed cells were incubated in TdT buffer containing 30 mM Trizma
base, pH 7.2, 140 mM sodium cacodylate, and 1 mM cobalt
chloride for 10 min at room temperature. A mixture of bio-16-dUTP
(Sigma) at 16.5 mM dATP (Boehringer Mannheim, Laval, QC,
Canada), and TdTenzyme at 5 U per mL (Boehringer Mannheim) in
TdT buffer was added and the reaction was allowed to proceed for
60 min at 371C. The reaction was terminated by addition of
2  SSC (300 mM sodium chloride plus 30 mM sodium citrate).
After washing the cells three times in ddH2O, endogenous
peroxidase activity was quenched in a 3% H2O2 solution for
10 min at room temperature. Cells were rinsed with PBS and non-
specific binding was reduced by incubation of cells with blocking
buffer (3% skim milk powder in PBS containing 0.5% Tween 20) for
15 min. The cells were incubated for 30 min at room temperature
with ExtrAvidin peroxidase (Sigma) diluted 1:50 in blocking buffer.
Cells were washed three times with ddH2O, and then stained
with aminoethyl carbizole at room temperature until a red color
appeared.
Cell proliferation of IDO-expressing skin cells [3H]thymidine
incorporation was employed to determine and compare the
proliferation rate between IDO- and non-IDO-expressing cells.
Fibroblasts and keratinocytes were infected with either nothing
(control), Ad-GFP (vector), or Ad-GFP-IDO (IDO) for 30 h. Free viral
particles were removed by washing with PBS and cells were
allowed to grow until day 3 or 6. Cells then received 1 mCi per mL of
[3H]thymidine (Amersham/Pharmacia Biotech) for 16 h, harvested
and washed three times with PBS. The radioactivity was
determined by scintillation counting.
Statistics All values are presented as mean  SD. The com-
parisons of cell proliferation between IDO- and non-IDO-expres-
sing cells were assessed using the non-parametric Fisher’s exact
test. A p-value of o0.05 was considered statistically significant.
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